Quality of Life in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy.
- Author:
Bosung SHIN
1
;
Taek Won KANG
Author Information
1. Department of Urology, Chonnam National University Medical School, Gwangju, Korea. sydad@hanmail.net
- Publication Type:Review
- Keywords:
Prostate Neoplasms;
Gonadotropin-releasing hormone;
Quality of life
- MeSH:
Gonadotropin-Releasing Hormone;
Humans;
Male;
Prostate*;
Prostatic Neoplasms*;
Quality of Life*;
Radiotherapy;
Recurrence
- From:Korean Journal of Urological Oncology
2016;14(1):10-17
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Androgen deprivation therapy (ADT) has been one of the standard protocol for treating prostate cancer. The role for hormonal treatment initially was restricted to men with metastatic and inoperable, locally advanced disease. Now it has been extended to neoadjuvant or adjuvant therapy for surgery and radiotherapy, for biochemical relapse after surgery or radiation, and even as primary therapy for non-metastatic disease. Although ADT can improve survival, it can also cause significant morbidity and a decrement in quality of life (QOL). In this article, we discuss QOL problem caused by ADT and suggest for mitigating harm of ADT.
